2. Lee EJ, Lee SY, In KH, Kim CH, Park S. Organizing pneumonia associated with oxaliplatin-combined chemotherapy: a case report. Med Princ Pract 2012;21:89-92.
3. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801.
4. Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N. DrugInduced interstitial lung disease: a systematic review. J Clin Med 2018;7:356.
5. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet PY, Brauner M, Kambouchner M, Huynh S, Naccache JM, Borie R, Piquet J, Mekinian A, Virally J, Uzunhan Y, Cadranel J, Crestani B, Fain O, Lhote F, Dhote R, Saidenberg-Kermanac’h N, Rosental PA, Valeyre D, Nunes H. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J 2017;50:1602419.
6. Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F, Wolf MK, Steinberg MH, Forsythe BH. National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 2005;14:775-787.
7. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-1357.
8. Hamada T, Yasunaga H, Nakai Y, Isayama H, Matsui H, Fushimi K, Koike K. Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. Respirology 2016;21:338-343.
9. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017;152:271-281.
10. Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 2014;105:1584-1590.
11. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014;43:613-626.
12. Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 2015;49:398-404.
14. Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 2008;102:273-279.
15. Sahin IH, Geyer AI, Kelly DW, O’Reilly EM. Gemcitabinerelated pneumonitis in pancreas adenocarcinoma: an infrequent event: elucidation of risk factors and management implications. Clin Colorectal Cancer 2016;15:24-31.
16. Dulohery MM, Maldonado F, Limper AH. Drug-induced pulmonary disease. In: Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus SC, Murray JF, Nadel JA, Slutsky AS, Gotway MB, editor. Murray and Nadel’s textbook of respiratory medicine. 6th ed. Philadelphia: W.B. Saunders; 2016. p. 1275-1294.
17. Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol 2010;99:693-700.
18. Lee EJ, Cardenes N, Alvarez D, Sellares J, Sembrat J, Aranda P, Peng Y, Bullock J, Nouraie SM, Mora AL, Rojas M. Mesenchymal stem cells reduce ER stress via PERK-Nrf2 pathway in an aged mouse model. Respirology 2020;25:417-426.
19. Lee SH, Lee EJ, Lee SY, Kim JH, Shim JJ, Shin C, In KH, Kang KH, Uhm CS, Kim HK, Yang KS, Park S, Kim HS, Kim YM, Yoo TJ. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res 2014;40:117-125.
20. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001;68:782-785. 789-795.
21. Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol 2000;175:1019-1024.
22. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 2014;83:231-239.
26. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:1607-1616.
27. Kato T, Masuda N, Nakanishi Y, Takahashi M, Hida T, Sakai H, Atagi S, Fujita S, Tanaka H, Takeda K, Satouchi M, Namba Y, Tamura T. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer 2017;104:111-118.
28. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
29. Padley SP, Adler B, Hansell DM, Müller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol 1992;46:232-236.
30. Piciucchi S, Romagnoli M, Chilosi M, Bigliazzi C, Dubini A, Beomonte Zobel B, Gavelli G, Carloni A, Poletti V. Prospective evaluation of drug-induced lung toxicity with highresolution CT and transbronchial biopsy. Radiol Med 2011;116:246-263.
31. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002;57:292-299.
32. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-748.
33. Takatani K, Miyazaki E, Nureki S, Ando M, Ueno T, Okubo T, Takenaka R, Hiroshige S, Kumamoto T. High-resolution computed tomography patterns and immunopathogenetic findings in drug-induced pneumonitis. Respir Med 2008;102:892-898.
34. Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J. Rituximabinduced lung disease: a systematic literature review. Eur Respir J 2010;35:681-687.
35. Terbuch A, Tiu C, Candilejo IM, Scaranti M, Curcean A, Bar D, Estevez Timon M, Ameratunga M, Ang JE, Ratoff J, Minchom AR, Banerji U, de Bono JS, Tunariu N, Lopez JS. Radiological patterns of drug-induced interstitial lung disease (DILD) in early-phase oncology clinical trials. Clin Cancer Res 2020;26:4805-4813.
37. Wild JM. Imaging pathophysiological changes in the lungs in IPF with xenon magnetic resonance imaging. Thorax 2018;73:1.
38. Morgan AR, Parker GJ, Roberts C, Buonaccorsi GA, Maguire NC, Hubbard Cristinacce PL, Singh D, Vestbo J, Bjermer L, Jogi J, Taib Z, Sarv J, Bruijnzeel PL, Olsson LE, Bondesson E, Nihlen U, McGrath DM, Young SS, Waterton JC, Nordenmark LH. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. Eur J Radiol 2014;83:2093-2101.
39. Zaher C, Hamer A, Peter T, Mandel W. Low-dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. N Engl J Med 1983;308:779.